Orchestra BioMed Holdings, Inc.
corporate_fare Company Profile
Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 19 items for OBIO at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 7/10. Across its 19 most recent items scored 7 or higher, the top rating is 9/10, with 8 rated 8 or above. Recent SEC coverage for OBIO spans 4, 10-Q, 424B5, SCHEDULE 13D/A.
Recent high-impact activity:
- 10% Owner RTW Buys $6M of Orchestra BioMed Stock at the $5.00 Offering Price
- Orchestra BioMed Q3 Loss Narrows to $18.8M; Cash Runway Extended to 2028
- Orchestra BioMed Prices $75M Offering at $5.00, a Discount to the $5.62 Last Sale
- Orchestra BioMed Prices 15M-Share Offering at $5.00
- Orchestra BioMed Launches Underwritten Stock Offering to Fund BACKBEAT and Virtue Trials
Financial Snapshot
Short Interest & Short Volume
6.99 days to coverFINRA reported short interest of 2,732,484 shares in OBIO as of the October 30, 2026 settlement, a 7.0% increase from the prior period — about 7.0 days to cover at its recent average daily volume. On November 20, 2026, 34.0% of OBIO volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for OBIO, detected from its recent SEC filings · based on capital-structure filings through 2026-11-06.
15M Shares Priced at $5.00 · Net Proceeds About $70.0M
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →